Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Deffered Revenue: 2016-2025

Historic Non-Current Deffered Revenue for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $8.3 million.

  • Tg Therapeutics' Non-Current Deffered Revenue fell 48.36% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 48.36%. This contributed to the annual value of $12.1 million for FY2024, which is 100.88% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Non-Current Deffered Revenue is $8.3 million, which was up 400.78% from $1.7 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Non-Current Deffered Revenue high stood at $16.2 million for Q3 2024, and its period low was $190,000 during Q3 2023.
  • For the 3-year period, Tg Therapeutics' Non-Current Deffered Revenue averaged around $5.3 million, with its median value being $3.7 million (2024).
  • Per our database at Business Quant, Tg Therapeutics' Non-Current Deffered Revenue skyrocketed by 8,408.42% in 2024 and then plummeted by 55.46% in 2025.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Non-Current Deffered Revenue stood at $457,000 in 2021, then slumped by 33.26% to $305,000 in 2022, then skyrocketed by 1,872.46% to $6.0 million in 2023, then surged by 100.88% to $12.1 million in 2024, then crashed by 48.36% to $8.3 million in 2025.
  • Its Non-Current Deffered Revenue stands at $8.3 million for Q3 2025, versus $1.7 million for Q2 2025 and $6.6 million for Q1 2025.